Zenas BioPharma is developing Obexelimab, a bifunctional monoclonal antibody that targets CD19 and FcγRIIb to suppress B cell activity, which is a key factor in autoimmune diseases. The company aims to provide effective therapies for patients suffering from these conditions, addressing significant unmet medical needs in immunology.
Funding
$200M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NVFounders
Product
Problem
Autoimmune diseases involve B cell hyperactivity, which significantly contributes to disease progression. Current treatments may not effectively suppress B cell activity, leaving unmet medical needs for patients suffering from these conditions.
Solution
Zenas BioPharma is developing Obexelimab, a bifunctional monoclonal antibody designed to target both CD19 and FcγRIIb, which are broadly expressed across the B cell lineage. By simultaneously engaging these targets, Obexelimab suppresses B cell activity, a key driver in many autoimmune diseases. This investigational drug is currently advancing through clinical trials, with the goal of providing effective therapies and addressing the unmet medical needs of patients with autoimmune disorders.
Target Audience
The primary target audience includes patients suffering from autoimmune diseases and the healthcare providers who treat them, specifically those seeking novel therapies to better manage B cell-mediated autoimmune conditions.
Features
- Bifunctional monoclonal antibody targeting CD19 and FcγRIIb
- Designed to suppress B cell activity by co-engaging CD19 and FcγRIIb
- Potential to address unmet medical needs in multiple autoimmune diseases
- Currently in clinical trials